VENOUS THROMBOSIS IN CHILDREN AND ADOLESCENTS WITH HODGKIN’S LYMPHOMA

2018 ◽  
Vol 97 (4) ◽  
pp. 30-36 ◽  
Author(s):  
D.A. Evstratov ◽  
◽  
P.A. Zharkov ◽  
A.V. Pshonkin ◽  
Y.G. Abugova ◽  
...  
Keyword(s):  
Venous Thrombosis ◽  
Children And Adolescents ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma

Treatment of classical Hodgkin’s lymphoma in children and adolescents

2019 ◽  
Vol 20 (10) ◽  
pp. 1227-1234 ◽  
Author(s):  
David Gómez-Almaguer ◽  
Oscar González-Llano ◽  
Valentine Jiménez-Antolinez ◽  
Andrés Gómez-De León
Keyword(s):  
Children And Adolescents ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma

The Impact of Latent Epstein-Barr Virus Infection on Outcome in Children and Adolescents with Hodgkin’s Lymphoma.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 3121-3121
Author(s):  
Alexander Claviez ◽  
Markus Tiemann ◽  
Heike Lueders ◽  
Reza Parwaresch ◽  
Guenther Schellong ◽  
...  
Keyword(s):  
Overall Survival ◽  
Children And Adolescents ◽  
Hodgkin’S Lymphoma ◽  
Epstein Barr Virus ◽  
Hodgkin's Lymphoma ◽  
Barr Virus ◽  
Ebv Infection ◽  
Nodular Sclerosis ◽  
Epstein Barr ◽  
The Impact

Abstract The prognostic significance of latent Epstein-Barr virus (EBV) infection in Hodgkin’s lymphoma (HL) is debated controversially. Especially in the pediatric age group, no conclusive data are available due to small series. 842 children and adolescents (55% male) with a median age of 13.7 years (range, 2–20) from consecutive pediatric DAL/GPOH multicenter treatment studies HD-90 and HD-95 were studied for the presence of latent EBV infection in Hodgkin and Reed-Sternberg cells by immunostaining against latent membrane protein 1 (LMP-1). Histology subtypes were as follows: nodular sclerosis (NSHL) 549, mixed cellularity (MCHL) 190, lymphocyte predominance (NLPHL) 90, lymphocyte depletion (LDHL) 6, lymphocyte-rich classical HL (LRCHL) 5, not specified 2. 88 patients had stage I, 470 had stage II, 172 had stage III and 112 had stage IV. B symptoms were present in 274 patients (33%). LMP status was compared with clinical parameters and established risk factors. A total of 263 patients (32%) were LMP positive. EBV infection correlated with gender (male 39% vs. female 23%; p<.001), histological subtype (MCHL 69% vs. NSHL 22% vs. NLPHL 6%; p<.001) and age (<10 years 67% vs ≥10 years 28%, p<.001. With a median follow-up of 4.9 years (0.3–12) 820 patients (97%) are alive. Probability of overall survival at 10 years (±SD) for EBV negative and positive patients was 98±1% and 95±1%, respectively (p=.017 by log-rank test). Probability of failure-free survival (FFS) in LMP positive and negative patients was 89±2% and 84±4%, respectively (p=.86). With respect to LMP status, a negative effect of latent EBV infection on overall survival became evident only for patients treated for advanced stages (p=.003), those with nodular sclerosis subtype Bennett II (p=.02) and B symptoms (p=.05). In a multivariate regression analysis, allocation to treatment group (RR=3.7) and LMP positivity (RR=3.01) were independent factors for overall survival and presence of B symptoms (RR=2.4) for FFS. Under current highly effective polychemotherapy with or without involved field radiotherapy in pediatric HL, latent EBV infection has no influence on FFS in univariate and multivariate analysis. LMP positivity, however, seems to be associated with an inferior overall survival in some subgroups.

Cancer/Testis Antigen CT45 Is Frequently Expressed in Hodgkin’s Lymphoma and Associated with Nodular Sclerosis Subtype and Advanced Disease.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 4591-4591 ◽  
Author(s):  
Alexander Claviez ◽  
Christine Mauz-Körholz ◽  
Hans-Jürgen Heidebrecht ◽  
Günther Schellong ◽  
Dieter Körholz ◽  
...  
Keyword(s):  
Children And Adolescents ◽  
Expression Pattern ◽  
Hodgkin’S Lymphoma ◽  
Advanced Disease ◽  
Hodgkin's Lymphoma ◽  
Histological Subtypes ◽  
Free Survival ◽  
Nodular Sclerosis ◽  
Ct Antigen ◽  
Cancer Testis

Abstract Cancer/testis (CT) antigens are members of a large tumor-associated protein family of increasing interest because of their diagnostic and possible therapeutic implications. Only few studies have investigated CT antigen expression in Hodgkin’s lymphoma (HL) so far. Recently, immunopurification of a 25/22-kDa antigen and sequencing revealed a peptide of 14 amino acids, which corresponds to the gene product of the newly described gene family MGC27005, located on chromosome Xq26.3, now termed CT45. The antigen shows a CT antigen-like expression pattern in human tissues and is detectable by the monoclonal antibody Ki-A10 generated after immunization of mice with HL-derived cell line L428. In this study, the expression pattern of CT45 in a large number of patients with HL included in subsequent pediatric multicenter treatment protocols of the GPOH was analyzed. Immunohistochemical results of Ki-A10 staining were correlated with histological subtype, immunophenotype, clinical data and outcome. In total, 1124 children and adolescents with HL diagnosed between 1978 and 2004 were studied. Median age of the patients was 13.7 years (range, 2.2 to 19.5) and 637 patients 02(57%) were male. Classical HL (cHL) was diagnosed in 988 patients (88%) and nodular lymphocyte predominant HL (NLPHL) was seen in 136 patients (12%). The group of cHL included 683 cases of nodular sclerosis HL (NSHL), 280 cases of mixed cellularity HL (MCHL), ten cases of lymphocyte-rich cHL (LRCHL), seven cases of lymphocyte-depleted HL (LDHL) and eight cases without subclassification. Nuclear CT45 expression was found in 526 cases (47%) with striking differences among histological subtypes and unrelated to CD30, CD20 and latent EBV infection. In NLPHL, 15% of cases scored CT45 positive in contrast to 51% of cases in cHL (p<.001). Within cHL, 58% of cases with NSHL were CT45 positive compared to 36% of cases with MCHL (p<.001). Aggressive histological variants of cHL (NSHL Bennett 2, LDHL) stained positive for CT45 in 62% of cases in comparison to 49% of other subtypes (p=.002). CT45 expression was associated with stage (p<.001), presence of B symptoms (p=.026), extranodal disease (p=.009) and allocation to treatment group (TG, p<.001). Fewer patients from TG1 (localized disease) were CT45 positive than patients from TG2/3 (intermediate and advanced disease; 38% vs. 53%, p<.001). With a median follow-up of 5.6 years, 97% of patients are alive. No significant differences were observed for overall survival, failure-free survival and event-free survival with respect to CT45 status. CT45 expression, which is restricted to neoplastic cells in HL, is found in a significant number of children and adolescents with HL, especially in cases of NSHL, aggressive histological subtypes and advanced disease. Due to effective polychemotherapy with or without low-dose radiotherapy, CT45 status did not emerge as an adverse prognostic factor in children and adolescents with HL in this series.

Lung changes in the late periods after using various chemoradiotherapy programs for Hodgkin’s lymphoma in children and adolescents

2017 ◽  
Vol 6 (2) ◽  
pp. 24
Author(s):  
R. A. Parkhomenko ◽  
O. I. Shcherbenko ◽  
N. V. Kharchenko ◽  
N. I. Zelinskaya ◽  
F. F. Antonenko ◽  
...  
Keyword(s):  
Children And Adolescents ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma

Evaluation of the Prognostic Meaning of C-reactive Protein (CRP) in Children and Adolescents with Classical Hodgkin’s Lymphoma (HL)

2012 ◽  
Vol 224 (06) ◽  
pp. 377-381 ◽  
Author(s):  
R. Haase ◽  
C. Vilser ◽  
C. Mauz-Körholz ◽  
D. Hasenclever ◽  
R. Kluge ◽  
...  
Keyword(s):  
Children And Adolescents ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
C Reactive Protein ◽  
Reactive Protein

Changes of the Heart Valves in the Long Term After Chemoradiotherapy According to Different Protocols for Hodgkin's Lymphoma in Children and Adolescents

2019 ◽  
Vol 8 (4) ◽  
pp. 410-416
Author(s):  
Roman A. Parkhomenko ◽  
Oleg I. Shcherbenko ◽  
Marina K. Rybakova ◽  
Natalya I. Zelinskaya ◽  
Natalya V. Kharchenko ◽  
...  
Keyword(s):  
Children And Adolescents ◽  
Hodgkin’S Lymphoma ◽  
Heart Valves ◽  
Hodgkin's Lymphoma
Sign in / Sign up

Export Citation Format

Share Document